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E-mail address: bakela.nare@scynexis.com (B. NarHuman African trypanosomiasis (HAT) is caused by the protozoan parasite Trypanosoma brucei, and the
disease is fatal if untreated. There is an urgent need to develop new, safe and effective treatments for HAT
because current drugs have extremely poor safety proﬁles and are difﬁcult to administer. Here we report
the development and application of a cell-based resazurin reduction assay for high throughput screening
and identiﬁcation of new inhibitors of T. b. brucei as starting points for the development of new treat-
ments for human HAT. Active compounds identiﬁed in primary screening of 48,000 compounds repre-
senting 25 chemical classes were titrated to obtain IC50 values. Cytotoxicity against a mammalian cell
line was determined to provide indications of parasite versus host cell selectivity. Examples from hit ser-
ies that showed selectivity and evidence of preliminary SAR were re-synthesized to conﬁrm trypanocidal
activity prior to initiating hit-to-lead expansion efforts. Additional assays such as serum shift, time to kill
and reversibility of compound effect were developed and applied to provide further criteria for advancing
compounds through the hit-to-lead phase of the project. From this initial effort, six distinct chemical ser-
ies were selected and hit-to-lead chemistry was initiated to synthesize several key analogs for evaluation
of trypanocidal activity in the resazurin-reduction assay for parasite viability. From the hit-to-lead
efforts, a series was identiﬁed that demonstrated efﬁcacy in a mouse model for T. b. brucei infection
and was progressed into the lead optimization stage. In summary, the present study demonstrates the
successful and effective use of resazurin-reduction based assays as tools for primary and secondary
screening of a new compound series to identify leads for the treatment of HAT.
 2012 Australian Society for Parasitology Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Human African trypanosomiasis (HAT) or sleeping sickness is
caused by the trypanosomatid protozoan parasite Trypanosoma
brucei. Trypanosome parasites are transmitted to humans through
a bite from the tsetse ﬂy insect vector. The two main trypanosome
species that cause HAT are theWest African variant (T. b. gambiense)
and the East African variant (T. b. rhodesiense) (Mauldin, 2006).
Without therapeutic intervention, trypanosomes migrate from the
bloodstream into the central nervous system (CNS) leading to a
second chronic stage of the disease that results in a coma and ulti-
mately death of the patient. Approximately 50 million people in
more than 20 sub-Saharan African countries are at risk of contract-
ing HAT and the World Health Organization (WHO) estimates that
30,000 new cases of HAT occur each (Brun et al., 2010;WHO, 2012).Published by Elsevier Ltd.
: +1 919 544 8697.
e).
Open acCurrent treatment options for HAT are very limited and not ideal
due to toxicity and requirement of lengthy parenteral administra-
tion, a situation that presents signiﬁcant challenges in endemic
areas with limited public health facilities and resources. The non-
CNS penetrating drugs pentamidine (T. b. gambiense) or suramin
(T. b. rhodesiense) are effective for treatment of acute disease (Stage
1) when the parasites are limited to the hemolymphatic system.
After parasites enter into the CNS (Stage 2 disease), patients are
generally treated with either the arsenic derivative melarsoprol or
the ornithine decarboxylase inhibitor eﬂornithine. Eﬂornithine is
only effective against the subspecies T. b. gambiense (Burchmore
et al., 2002) and is difﬁcult to administer in the disease endemic
region. Melarsoprol is particularly unsafe because it causes reactive
encephalopathy in 5–10% of patients, and 50% of these patients die
from this adverse reaction (Pépin and Milord, 1994; Brun et al.,
2001). Of particular concern is the increased incidence of melarso-
prol treatment failures of up to 25% that have been reported in
endemic areas (Brun et al., 2001). Additionally, trypanosomescess under CC BY-NC-ND license.
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(VSG), to evade the host immune response, and this has severely
limited options for vaccine development as a means to control
HAT (Pays, 1995). Consequently, chemotherapy remains a major
tool for HAT control efforts, and this clearly requires new, safe
and effective drugs.
To accelerate the discovery of novel leads for the treatment of
HAT, it is essential to have a simple, robust and inexpensive assay
to identify and advance suitable chemical starting points targeting
T. b. brucei. The assay should serve as a tool for high throughput
screening (HTS) to assess large sets of chemical libraries and prior-
itize newly synthesized analogs in hit-to-lead and lead optimiza-
tion phases of the discovery process. The establishment of a
simple in vitro cell culture system for axenic growth of T. b. brucei
(Baltz et al., 1985; Hirumi and Hirumi, 1989; Kaminsky and
Zweygarth, 1989) has led to the exploration of a variety of whole
cell assay formats (Muskavitch et al., 2008) for the identiﬁcation
of compounds with anti-trypanosomal properties. For evaluating
viability following exposure to test compounds, the Alamar Blue™
(resazurin) (Räz et al., 1997; Sykes and Avery, 2009) and Cell-
Titer-Glo™ luminescent cell viability assay (Mackey et al., 2006)
methods have emerged as those most amenable to HTS because
of their high signal-to-background ratio and reproducibility. The
resazurin assay is preferred due to lower cost and has been used
for quantitative evaluation of the proliferation of various cell types
including human cell lines (Ahmed et al., 1994; O’Brien et al.,
2000), fungi (Tiballi et al., 1995), bacteria (Baker and Tenover,
1996; Franzblau et al., 1998) and protozoan parasites (Räz et al.,
1997; Shimony and Jaffe, 2008; Sykes and Avery, 2009; Nare
et al., 2010). Resazurin is an oxidation–reduction sensitive dye that
changes color and ﬂuorescence properties upon reduction by living
cells. Only viable cells generate a ﬂuorescent signal because they
are metabolically active. These properties of resazurin have been
exploited to provide a quantitative measurement of parasite prolif-
eration and viability to identify a variety of inhibitor compounds.
The incorporation of such a robust and reliable assay into a drug
discovery screening cascade could play a key role in advancement
of T. b. brucei hits through hit-to-lead and lead optimization
phases.
Here we report the development and application of a simple
and inexpensive resazurin-reduction T. b. brucei cell-based HTS
assay for primary screening and hit-to-lead progression of new
lead chemical series for the treatment of HAT. The assay mea-
sures the ability of T. b. brucei parasites to metabolize resazurin
after a 72 h incubation in the presence of test compounds. Using
this assay, a library of 48,000 SCYNEXIS proprietary com-
pounds representing 25 unique chemical classes was screened
at a nominal concentration of 2 lg/mL. Compounds showing
>75% inhibition were selected and their IC50 determined using
a triplicate 10-point titration procedure. In parallel, these com-
pounds were evaluated in a similar resazurin-based cytotoxicity
assay in mouse L929 ﬁbroblasts to facilitate identiﬁcation of
broadly biocidal compounds. Screening data from each series
was examined for preliminary structure–activity relationships
(SARs) for trypanocidal activity, and those showing selectivity
for trypanocidal activity relative to cytotoxicity were progressed
into a variety of secondary assays to select candidates for hit-to-
lead optimization in an integrated drug discovery program. Key
secondary assays included assessment of changes in potency in
the presence increasing serum, time to kill measurements and
determinations of reversibility of trypanocidal effects following
transient exposure to test inhibitor. Based on proﬁling and prior-
itization of newly synthesized compounds from the hit-to-lead
effort using the resazurin-based trypanocidal and cytotoxicity
assays, a lead class with efﬁcacy in the mouse model for HAT
was identiﬁed.2. Materials and methods
2.1. Parasite and cell culture
The bloodstream-form trypanosome T. b. brucei 427 strain was
used in all assays for assessment of compound sensitivity in vitro.
Parasiteswere routinely cultured in T-25 vented cap ﬂasks (Corning
Incorporated, NY) and kept in humidiﬁed incubators at 37 C and 5%
CO2. The parasite culture media was complete HMI-9 medium
(Hirumi and Hirumi, 1989) containing 10% FBS, 10% serum plus
(JRH Biosciences Inc., Lenexa, KS) 100 units penicillin and
0.1 mg/mL streptomycin. To ensure log growth phase, trypano-
somes were sub-cultured every 2–3 days at a dilution of 1:100 in
fresh HMI-9 medium. L929mouse ﬁbroblast cells (ATCC, Manassas,
VA) were maintained as adherent cultures in Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM) (Invitrogen, Carlsbad, CA) supplemented
with 10% FBS and 100 units penicillin and 0.1 mg/ml streptomycin.
2.2. Optimization of resazurin reduction to measure T. brucei viability
To determine the relationship between cell number and resazu-
rin ﬂuorescence signal, T. b. brucei parasites were serially diluted
(100 lL) into 96-well tissue culture plates from a stock solution
with 1  107/mL. A stock solution of resazurin was prepared in Dul-
becco’s phosphate buffered saline (D-PBS) at 12.5 mg/mL and vari-
ous concentrations (5–20 lL/well) were tested by incubation with
parasites at 37 C. Fluorescence due to reduction of resazurin by via-
ble parasites was read on the EnVision ﬂuorometer (kex = 544 nm;
kem = 590 nm) (Perkin Elmer) following incubation periods of up
to 8 h. For determination of ideal seeding density for compound
evaluation, T. b. brucei parasites were plated into 96-well plates at
various starting densities and incubated at 37 C and 5% CO2 for
72 h prior to addition of resazurin and assessment of viability.
2.3. In vitro compound sensitivity assayand high throughput screening
To prepare for assay, T. b. brucei parasites in the log phase of
growth were diluted 1:10 in HMI-9 media, and 10 lL was counted
using a hemocytometer. Parasites were diluted to 2  105/mL in
HMI-9 to generate a 2working concentration for assay to evaluate
trypanocidal activity. For HTS, compoundswere added to test plates
to achieve a ﬁnal concentration of 2 lg/mL. For IC50 determination,
compounds were serially diluted in dimethyl sulphoxide (DMSO)
and 0.5 lL added to 50 lL HMI-9 into 96-well plates using Biomek
NX liquid handler (Beckman Coulter, Fullerton, CA). Parasites from
the diluted stock were added to each well (50 lL) using aMultidrop
384 dispenser (Thermo Electron Corporation) to give a ﬁnal concen-
tration of 1  105/mL parasites and a ﬁnal DMSO concentration of
0.5%. After 72 h of incubation at 37 C and 5% CO2, resazurin
(20 lL of 12.5 mg/mL stock in phosphate buffered saline)was added
to each well using a Multidrop 384 dispenser (Fisher Scientiﬁc) and
plates were incubated at 37 C for 4–6 h or until a signal to back-
ground ratio of 8–10-fold was achieved. Fluorescence was read on
an EnVision plate reader as described in the optimization protocol.
Compounds showing P75% inhibition when tested at 2 lg/mL
were evaluated in a 10-point dose response, 2-fold dilution exper-
iment starting at 5 lg/mL. For calculation of IC50 values, sigmoidal
dose response curves were generated using XLﬁt curve ﬁtting soft-
ware from IDBS (Guilford, UK). IC50 is deﬁned as the amount of
compound required to decrease cell viability of T. brucei by 50%
compared to those grown in the absence of test compound.
2.4. Mammalian cell cytotoxicity assay
To prepare for assay, L929 cells in log growth phase were re-
moved from the T-25 ﬂask using 1 mL of 0.05% trypsin and a
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cell concentration. Cells were diluted to 2  104/mL in DMEM to
prepare for plating, and 100 lL of cells was added to a 96-well
plate using a Multidrop 384 dispenser. Cells were allowed to ad-
here for 24 h prior to removal of plating media and replacement
with 50 lL of fresh medium into each of the wells. Compounds
to be tested were serially diluted in DMSO and 0.5 lL of the dilu-
tions added to the 50 lL of DMEM already in the plates. An addi-
tional 50 lL of DMEM was added using a Multidrop 384
dispenser to ensure proper compound mixing within each well
and to achieve the desired starting concentration. After 72 h of
incubation at 37 C and 5% CO2, resazurin was added and the ﬂuo-
rescence signal allowed to develop for 3–4 h until a signal to back-
ground ratio of 10-fold was achieved prior to reading and data
evaluation as described for the T. b. brucei assay.2.5. Serum shift assay
To assess the potential effects of protein binding on trypanoci-
dal activity, parasite viability assays were performed in the pres-
ence of increasing concentrations (2.5–20%) of FBS. Serum plus
was not added to the HMI-9 media used in this assay because
the supplement contains up to 12% bovine serum. T. b. brucei were
conditioned to the test serum concentration for at least one round
of passage prior to assay. Compound addition, incubation, signal
detection and IC50 determinations were conducted as described
in the general T. b. brucei screening assay. Compound activity
was also evaluated on parasites in the presence of horse or mouse
serum added to a ﬁnal concentration of 10%.2.6. Time to kill assay
Determination of compound-mediated killing of T. b. brucei
in vitro over time (i.e. time to kill) was conducted using the CellT-
iter-Glo™ reagent (Promega Inc., Madison, WI) to measure parasite
ATP content as a real time indicator of viability. Test compounds
were serially diluted into white clear-bottom 96-well plates (Corn-
ing Inc. Life Sciences, Lowell, MA) containing HMI-9 media (50 lL/
well), and parasites were added at a concentration of 2  105/mL
(50 lL/well) to duplicate plates for each evaluation time point. At
the selected time, 45 lL of CellTiter-Glo™ reagent was added to
each set of duplicate plates. The contents of the wells were mixed
to lyse the parasites, and plates were incubated in the dark for
10 min and read on the EnVision plate reader using a luminescence
protocol.2.7. Test for reversibility of trypanocidal effects
To establish the time required to cause persistent or irreversible
effects by test compounds, T. b. brucei parasites were assessed for
their ability to recover from transient exposure to test compounds.
Parasites were seeded in 96-well plates at 1  106/mL (100 lL/
well) and incubated with serially diluted test compound. One plate
was prepared for each time point, and at the designated time, a
plate was removed and centrifuged at 4,400 rpm for 5 min to sed-
iment the parasites. The supernatant was aspirated and 100 lL of
warmed HMI-9 was added to the plate. The plate was then re-
turned to the centrifuge, and this process was repeated for a total
of three washes. Parasites were re-suspended in 100 lL of warmed
media and 20 lL of this suspension was added to 80 lL of HMI-9
media in triplicate plates. Following a 72 h incubation, resazurin
was added and trypanocidal activity determined as described for
the in vitro sensitivity assay.2.8. Efﬁcacy in the mouse model for acute HAT
For efﬁcacy studies against acute infections, groups of three
female Swiss Webster mice (Ace Animals, Boyertown, PA) were in-
jected intraperitoneally (i.p.) with freshly drawn infected rat blood
containing 500 trypanosomes (T. b. brucei EATRO 110 strain). Test
compounds were formulated in 20% ethanol/50% polyethylene
glycol 400% and 30% carboxymethylcellulose and given at 200 lL
per 25 g animal orally or via i.p. injection. Animals were monitored
daily for a period of 30 days for signs of compound toxicity and
clinical disease. After the end of the each dosing period, parasite-
mia was checked twice weekly by microscopy using smears
prepared from tail vein blood. Animals remaining parasite free
for more than 30 days beyond the end of the treatment period
were considered cured (Bacchi et al., 1996).
3. Results and discussion
The trypanosomatid protozoan parasites T. b. brucei grow quite
robustly under axenic conditions in vitro, and they reach sufﬁcient
density in microtiter plates to produce a readily detectable ﬂuores-
cence signal upon incubation with resazurin. When added at
20 lL/well, from a 25 mg/mL stock, resazurin is reduced linearly
over a 3–4 h period after which there appears to be a saturation
of the ﬂuorescence signal, particularly at high parasite densities
(Fig. 1A). The maximum density reached in the control wells is in
the range of 2–5  106/mL and the signal to background (S/B) ratio
is 8–10-fold following incubation with resazurin. The S/B for T. b.
brucei reported in the current study is lower than that reported
for T. b. rhodesiense (15:1) and much higher than the 3:1 obtained
with T. b. gambiense (Räz et al., 1997). These differences can be
attributed to either low dehydrogenase activity responsible for
metabolizing resazurin or reduced uptake of the dye substrate. Dif-
ferences in the composition of media used to culture trypanosomes
could potentially account for some of the variation observed in
studies from different laboratories.
For plate based assays, T. b. brucei parasites were seeded at
1  105/mL which resulted in a low level or non-detectable level
of ﬂuorescence at the start of the assay process and a 10-fold in-
crease in signal after the 72 h assay period. From studies of DMSO
amounts to be used in the assay, 0.5% was the maximum concen-
tration that did not result in negative effects on parasite growth
during the assay (data not shown). This level of DMSO tolerance
in the assay is consistent with that reported previously from other
studies (Räz et al., 1997; Sykes and Avery, 2009). To assess plate
uniformity and signal to noise, the maximum, median and mini-
mum signal for developing the HTS assay was determined using
0.4% DMSO, 5 ng/mL and 2,000 ng/mL of pentamidine respectively
(Fig. 1B). The typical Z0 for the assay was 0.7–0.9 and this parame-
ter is used to accept results from screening activities. Results from
this experiment suggest that the resazurin assay is capable of dis-
criminating among compounds with different levels of inhibition
(0–100%) in the T. b. brucei viability assay during the screening pro-
cess. In addition to primary screening, the resazurin-reduction as-
say was evaluated for its suitability for the assessment of IC50
values to allow for comparison of compounds during the screening
and hit progression efforts. Previous studies have determined that
IC50s from the resazurin-based assay are comparable to those ob-
tained using other ﬂuorophores, e.g. BCECF-AM (Räz et al., 1997)
to assess parasite viability. In this study, we found that measure-
ment of T. b. brucei IC50 values using resazurin assay or the more
expensive Cell-Titer-GLO assay (Mackey et al., 2006) yielded very
comparable results (data not shown). Dose response curves and
IC50 values for the reference compounds pentamidine and suramin
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Fig. 1. (A) Correlation between the numbers of T. b. brucei parasites and resazurin reduction signal. Serial two-fold dilutions of parasites starting at 1  107/mL were prepared
in 100 lL followed by addition of resazurin and ﬂuorescence measurement to determine parasite viability. (B) Validation of T. b. brucei automated screening assay. T. b. brucei
parasites were treated with 0.4% DMSO, 5 ng/mL pentamidine (50% inhibition) or 100 ng/mL pentamidine (100% inhibition) to produce maximum, median and minimum
ﬂuorescence signal upon addition of resazurin. (C) Dose response of pentamidine and suramin on T. b. brucei growth following 72 h incubation in the presence of inhibitors.
Data represents averages of triplicate determinations measured as a percentage of the resazurin signal in the absence of compound.
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ues are consistent with those reported in the literature (Räz et al.,
1997; Sykes and Avery, 2009).
Using conditions established in the optimization phase, the res-
azurin-based assay was used to screen a48,000 small molecule li-
brary in which each compound was added at a ﬁnal concentration
of 2 lg/mL. The library consisted of approximately 25 distinct
structural classes with approximately 2,000 compounds per chem-
ical class. Each screening plate contained 88 test compounds, pent-
amidine (wells A1 and B1), suramin (wells C1 and D1) and DMSO in
wells E1-H1 to enable calculation of% inhibition of parasite viability
usingmaximum (DMSO) andminimum (pentamidine and suramin)
signals. Using an inhibition cut-off ofP75%, which corresponds to
the mean + 3 standard deviations of all the screen values, approxi-
mately 1,106 compounds (2.3% hit rate) were selected for further
evaluation (Fig. 2A and B). In order to conﬁrm trypanocidal activi-
ties observed in the primary screen, all actives were subjected to
dose response analysis starting at 5 lg/mL and compound series
with representative analogs which exhibited IC50s 61 lg/mL were
advanced into the next phase of testing. Additionally, to progress
into the next phase of testing, actives from the primary HTS cam-
paign were required to show selectivity for parasites versus mam-
malian cells grown under similar conditions. Therefore, all HTS hits
were tested for cytotoxicity against the L929 mouse ﬁbroblast cell
line. In cases where the majority of T. b. brucei active members of
a chemotype showed cytotoxicity towards mammalian cells, the
entire series was deprioritized for progression into hit-to-lead
phase. The result of this evaluation led to the selection of 150 com-
pounds from six chemical classes which exhibited the desired com-
bination of in vitro potency against T. b. brucei, low cytotoxicity
towards mammalian cells and some evidence of preliminary SAR(Fig. 2B). The six distinct chemical series with the total numbers
screened per series and selections for dose response analysis are
shown in Table 1.
After preliminary screening and hit conﬁrmation, a hit-to-lead
effort was initiated on six selected chemotypes (Table 1). Newly
synthesized compounds were evaluated in dose response with T.
b. brucei and cytotoxicity testing with L929 cells. Representative
compounds from the synthetic efforts were progressed into a vari-
ety of secondary biological assays to assess serum shift (protein
binding), time to kill and reversibility of compounds effects
(Fig. 4). The serum shift assays measured changes in IC50 values
by using the resazurin-based T. b. brucei viability assay in the pres-
ence of increasing concentration of serum (2.5–20%). This process
serves as an early indicator of potential impact of compound bind-
ing to serum protein on potency against T. b. brucei. Serum shift
analysis on hit-to-lead compounds in this study is exempliﬁed
using representatives from three different hit series (Fig. 3). Sulfan-
ilides and amidoximes show a signiﬁcant shift in IC50s when serum
is increased from 2.5% to 20% (20–30-fold shift) while arylazoles
are not affected (<3-fold shift). Based on these ﬁndings, part of
the early synthetic effort on sulfanilide and amidoxime optimiza-
tion focused on reducing lipophilicity which appears to be a major
contributor to serum protein binding. The chemical stability of sul-
fanilides was found to vary widely under aqueous conditions in the
presence or absence of serum and this series was discontinued. For
arylazoles, the key liability was the narrow selectivity for parasite
vs. mammalian cells and the series was ultimately dropped for this
reason (Table 2).
Because our compound progression criteria require demonstra-
tion of efﬁcacy in the mouse model to be characterized as leads
(Fig. 4), we proﬁled the potency of various newly synthesized
AB
C
Fig. 2. (A) Frequency distribution of the 47,470 compounds based on the resazurin viability signal after 72 h incubation of T. b. brucei in the presence of 2 lg/mL compound.
Based on these data, a cut-off ofP75% inhibition (3 SD) was used to selective actives for progression in the next step of the screening cascade. (B) HTS and follow-up strategy
for trypanocidal screening using the resazurin assay. Funneling of the 47,470 compounds through a variety of assays and selection of ideal lead series to enter hit-to-lead
optimization phase is shown. (C) Structures and IC50 for representative compounds from the hit series that entered hit-to-lead activities.
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um. To do this, T. b. brucei parasites were adapted to grow in the
presence of 10% mouse serum prior to determination of IC50s on
representative compounds from the six chemotypes. Compounds
from the amidoxime chemotype were found to be completelyinactive in the presence of mouse serum. All the other series dis-
played essentially equivalent potency in both mouse and bovine
serum (data not shown). While the amidoxime hit to lead effort
identiﬁed compounds with sub-micromolar activity against T. b.
brucei in vitro, further exploitation of this chemotype was limited
Table 1
Hit classes identiﬁed from primary screening of T. b. brucei using the resazurin-
reduction HTS assay and selected for progression into hit-to-lead phase.
Compound classa Screenedb Hitsc Hit rate (%)
Aminoketones 779 61 8
Pyramidoximes 2151 240 11
Arylazoles 2239 52 2
Aminooxazoles 2339 159 7
Sulfanilides 1130 23 2
Heterocyclic ketones 3985 302 8
a Chemical series that were selected after HTS for further investigation.
b Total number of analogs screened from each of the libraries that showed
selectivity and evidence of SAR following analysis of HTS using cell-based T. b.
brucei assay.
c Number of compounds in each library that showP75% inhibition of T. b. brucei
when screened at a nominal concentration of 2 lg/mL in the HTS assay.
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Fig. 3. Shift in trypanocidal activity of compounds in the presence of different concentra
test compound in the presence of increasing concentrations (2.5–20%) of bovine serum.
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understanding of the mechanisms that limit efﬁcacy of amidox-
imes in the presence of mouse serum is required before this series
could be developed any further as a potential drug candidate for
the treatment of HAT. Interestingly, compounds from this class
were also inactive in the presence of horse serum, which is often
used in place of bovine serum in T. b. brucei culture (Kaminsky
and Brun, 1998). Amidoxime compounds with reasonable in vitro
pharmacokinetic properties were found to be inactive in the
in vivo mouse model for HAT, consistent with lack of trypanocidal
activity against the parasite in vitro when assays are conducted in
the presence of mouse serum.
To initiate a preliminary understanding of the pharmacodynam-
ics of the early hit-to-lead compounds, time to kill studies were
conducted in which the ATP-dependent luciferase assay was used0.001 0.01 0.1 1 10
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Parasite viability was determined after 72 h using resazurin reduction assay.
In Vivo Mouse Model 
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Fig. 4. Overall strategy and screening cascade for the discovery and progression of new treatment for human African trypanosomiasis. Actives from high throughput
screening with the resazurin-based whole cell T. b. brucei assay where evaluated against mammalian cells to determine parasite versus host cell selectivity. Hits from this
process were re-synthesized to conﬁrm activity prior to initiation of hit-to-lead expansion. Compounds from the hit-to-lead process were evaluated in a series of assays to
determine physico-chemical properties, metabolic stability, permeability, changes in potency in the presence of serum, time to kill kinetics and reversibility of trypanocidal
effects. Representative analogs from each of the hit-to-lead series were evaluated for efﬁcacy in a mouse model for acute HAT prior to initiation of lead optimization process
to develop compounds with the ability to cure Stage 2 disease.
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Fluorescence signal development in the resazurin assay requires
as least 3–4 h to assess parasite viability and is therefore not
appropriate for time to kill assays where instant measurement of
viability is essential. Representative compounds from the amidox-
ime and arylazole chemotypes displayed rapid parasite killing with
signiﬁcant reduction in parasite viability in the ﬁrst 3 h of incuba-
tion with inhibitors. Maximum IC50 values achieved within 24 h
(Table 3) were similar to those observed when parasites where
incubated for 72 h in the presence of inhibitors, suggesting rapid
cidal action. In contrast, aminooxazoles and heterocyclic ketones
showed very limited effects on parasites in the ﬁrst 3–6 h, and
IC50s on representative compounds from this class were
signiﬁcantly higher at 24 h than at 72 h, suggesting slower onsetTable 2
Summary of hit-to-lead activities on select HTS leads from T. b. brucei screening.
Compound class HtLa Best activeb
Aminoketones 31 15 lM
Pyramidoximes 161 70 nM
Arylazoles 278 200 nM
Aminooxazoles 53 3.8 lM
Sulfanilides 122 205 nM
Heterocyclic ketones 301 5 nM
a Total number of analogs synthesized to explore SAR around the original hits.
b Most potent compound synthesized during the hit to lead phase and results are IC50
c Denotes a measure of the difference in IC50 for parasite versus cytotoxicity toward t
d Final decision made on each of the HtL series based on proﬁling newly synthesized
e Mice with an acute T. b. brucei infection were cured with a 40 mg/kg daily dose forof trypanocidal effects (Table 3). Control compounds suramin and
pentamidine displayed time to kill kinetics intermediate between
these two groups of newly synthesized hit-to-lead compounds.
Time to kill kinetic studies have been used effectively to correlate
T. b. brucei parasite killing in vitro with that observed in vivo and
thus predict dose regimens required to achieve efﬁcacy in vivo
(Jacobs et al., 2011). Although fast killing mechanisms could poten-
tially arise from non-speciﬁc effects on parasites, the amidoxime
class of compounds displayed good SAR and selectivity for parasite
versus mammalian host cell killing. In contrast, the arylazole class
was ultimately dropped for poor or ﬂat SAR and lack of selectivity
for mammalian cell versus parasite killing.
Representatives from hit-to-lead series were also evaluated
in vitro to determine the reversibility of trypanocidal effects usingSelectivityc Series outcomed
47 Insufﬁcient potency
>143 Inactive in mouse serum
20 Limited selectivity
>6 Insufﬁcient potency
>500 Poor properties
>2000 Active in mouse modele
values for killing T. b. brucei parasites as measured by the resazurin reduction assay.
he L929 ﬁbroblast cells.
analogs through a variety of biological assays.
4 days of representative compounds from this class (Mercer et al., 2011).
Table 3
Time-dose response (time to kill) IC50 values for exposure of T. b. brucei to
representative series synthesized in the hit-to-lead phase.
Compound Class 3 h 6 h 24 h 72 h
Pyramidoximes 0.450 0.141 0.098 0.07
Arylazoles 1.004 0.130 0.234 0.21
Aminooxazoles >10 >10 2.310 1.64
Heterocyclic ketones >10 >10 1.453 0.04
Pentamidinea >2.94 >2.94 0.015 0.0065
Suramina >7 >7 0.19 0.1
Assays were conducted starting at 10 lM and IC50 values were determined from 10-
point dose response curves using Cell-Titer Glo reagent following compound
exposure for the indicated times.
a Indicated values (lM) are IC50s for T. b. brucei following compound exposure.
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in the absence of inhibitor compound for up to 72 h. Because this
assay involves removal or wash-out of compounds at various
points after treatment (Nare et al., 2010; Jacobs et al., 2011), fol-
lowed by incubation for up to 72 h, we were able to use the resa-
zurin assay to measure parasite viability as an indicator of the
ability of the parasites to recover from compound effects. In these
experiments (Table 4), we demonstrate that a short exposure
(1–3 h) to arylazole or amidoxime compounds is sufﬁcient to pro-
duce irreversible effects on the survival of trypanosome cultures
in vitro. The inability of T. b. brucei to recover from transient expo-
sure suggests that enough arylazole or amidoxime compound is re-
tained within the parasites or that they exert irreversible effects on
the appropriate parasite biology during this limited time frame.
Implications for compounds with fast and irreversible mechanism
of killing are that high serum concentration is likely to be required
for a short period of time to achieve in vivo efﬁcacy. In contrast,
parasites exposed to heterocyclic ketones and aminooxazoles dem-
onstrated essentially full recovery following short exposure (1–2 h)
but signiﬁcant non-reversible effects were evident within in-
creased exposure time. This suggests that the latter classes of com-
pounds are either slow acting or that there is reversible interaction
with the target site of action within the parasites. Suramin and
pentamidine are known to accumulate in trypanosomes through
endocytosis (Fairlamb and Bowman, 1980) and the P2 transporter
(Mathis et al., 2006) respectively and their effects following short
exposure (3–6 h) suggest that sufﬁcient compound is accumulated
and retained after the wash-out procedure.
Representative compounds from each of the key hit-to-lead
series were evaluated in a mouse model for acute HAT. Compounds
were administered twice daily by the intraperitoneal route to max-
imize exposure, as full pharmacokinetic analysis was not available
in this early phase. As shown in Table 2, only representative
compounds derived from the heterocyclic ketone synthetic effort
demonstrated activity when given at 20 mg/kg twice daily for
4 days. Properties of this class of compounds, including the poten-Table 4
Evaluation of reversibility of compound trypanocidal effect in vitro.
Compound Class 1 h 3 h 6 h 72 h
Pyramidoximes 3.50 0.82 0.54 0.07
Arylazoles 20.18 3.81 1.80 0.21
Aminooxazoles >23.06 >23.06 >2.06 3.78
Heterocyclic ketones >22.40 >22.40 0.51 0.04
Pentamidine >2.94 1.2 0.28 0.004
Suramin >7 2.8 0.86 0.05
To establish time or concentration required to cause irreversible effects, T. b. brucei
parasites were incubated with increasing concentration of test compounds. At
indicated times samples were withdrawn and compounds were washed out
through centrifugation. Viability was assessed after incubation in compound-free
medium for 72 h and IC50s were determined and reported in lM.tial molecular target that is the basis for the anti-parasitic activity
have been reported in recent publications (Mercer et al., 2011;
Perales et al., 2011). The progression of this series of compounds
for use in the treatment of Stage 2 HAT in a mouse model was
limited by our inability to balance the permeability across the
blood–brain barrier with retention of sufﬁcient potency against
T. b. brucei to achieve efﬁcacy.
In summary, we have developed and deployed a resazurin-
reduction based whole cell T. b. brucei assay to screen a proprietary
library of 48,000 compounds representing 25 different structural
classes. Representative compounds from six chemotypes were
selected for further characterization because they exhibited the de-
sired combination of in vitro potency, low cytotoxicity to mamma-
lian cells, i.e. selectivity and some evidence of preliminary SAR. A
hit-to-lead program was initiated to follow-up actives from ﬁve
chemical series and newly synthesized analogs were evaluated
through a variety of secondary assays, most of which were depen-
dent on measurement of parasite viability using the resazurin-
reduction signal measurement. In vivo efﬁcacy was achieved with
one of the ﬁve hit-to-lead series, thus validating the assays and
screening strategy described in this work.Acknowledgements
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